BTIG Research Reiterates “Buy” Rating for Ardelyx (NASDAQ:ARDX)

Ardelyx (NASDAQ:ARDX)‘s stock had its “buy” rating reissued by research analysts at BTIG Research in a report released on Friday,Benzinga reports. They currently have a $17.00 price objective on the biopharmaceutical company’s stock. BTIG Research’s target price suggests a potential upside of 196.68% from the stock’s current price.

ARDX has been the subject of several other reports. Wedbush raised their target price on shares of Ardelyx from $16.00 to $19.00 and gave the company an “outperform” rating in a research note on Wednesday, January 21st. Jefferies Financial Group reiterated a “buy” rating and set a $15.00 price objective on shares of Ardelyx in a report on Tuesday, January 27th. Raymond James Financial restated a “strong-buy” rating and set a $19.00 target price on shares of Ardelyx in a research note on Thursday, January 8th. TD Cowen reaffirmed a “buy” rating on shares of Ardelyx in a research report on Thursday, January 29th. Finally, Citigroup increased their price target on Ardelyx from $11.00 to $14.00 and gave the company a “buy” rating in a research note on Friday, January 9th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $15.09.

Ardelyx Price Performance

ARDX opened at $5.73 on Friday. The business’s 50-day moving average is $6.77 and its two-hundred day moving average is $6.11. Ardelyx has a 1 year low of $3.21 and a 1 year high of $8.40. The company has a debt-to-equity ratio of 1.31, a current ratio of 4.41 and a quick ratio of 4.11. The firm has a market capitalization of $1.39 billion, a PE ratio of -22.92 and a beta of 0.57.

Ardelyx (NASDAQ:ARDX) last released its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.03). Ardelyx had a negative net margin of 15.12% and a negative return on equity of 42.05%. The firm had revenue of $125.22 million for the quarter, compared to analysts’ expectations of $118.04 million. During the same period in the previous year, the company posted $0.02 earnings per share. The business’s quarterly revenue was up 7.8% compared to the same quarter last year. Research analysts anticipate that Ardelyx will post -0.18 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Ardelyx news, insider Laura A. Williams sold 50,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $6.98, for a total transaction of $349,000.00. Following the completion of the transaction, the insider directly owned 361,563 shares of the company’s stock, valued at approximately $2,523,709.74. This trade represents a 12.15% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 4.80% of the company’s stock.

Institutional Trading of Ardelyx

Hedge funds and other institutional investors have recently made changes to their positions in the business. DCF Advisers LLC acquired a new position in Ardelyx during the second quarter valued at $39,000. Brighton Jones LLC purchased a new position in shares of Ardelyx during the 2nd quarter valued at about $40,000. First Horizon Corp lifted its holdings in shares of Ardelyx by 120.4% in the 4th quarter. First Horizon Corp now owns 7,906 shares of the biopharmaceutical company’s stock valued at $46,000 after buying an additional 4,319 shares during the period. SBI Securities Co. Ltd. grew its holdings in Ardelyx by 147.0% during the third quarter. SBI Securities Co. Ltd. now owns 10,253 shares of the biopharmaceutical company’s stock worth $56,000 after acquiring an additional 6,102 shares during the period. Finally, Swiss Life Asset Management Ltd purchased a new position in Ardelyx during the third quarter valued at approximately $57,000. Institutional investors and hedge funds own 58.92% of the company’s stock.

Trending Headlines about Ardelyx

Here are the key news stories impacting Ardelyx this week:

• Positive Sentiment: Strong commercial growth — IBSRELA revenue grew 73% in 2025 to $274.2M and total revenues reached $407.3M, demonstrating meaningful top-line momentum that supports future cash flow potential. Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Revenue beat — Q4 revenue of $125.2M topped analyst estimates (~$118M), showing continued commercial execution even as EPS missed. MarketBeat Q4 results summary
• Positive Sentiment: Bullish analyst support — BTIG reaffirmed a buy rating and set a $17 price target, and at least one firm reportedly raised its target sharply (~+80%), showing divergent analyst views and potential upside if sentiment improves. Benzinga note on BTIG rating
• Neutral Sentiment: Earnings call and disclosures — the full Q4 earnings call transcript is available; management reiterated the XPHOZAH access strategy and said the company is well-capitalized to pursue growth and development programs. Investors will parse the call for guidance on margins and R&D spend. Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Data noise on short interest — several data feeds reported large short-interest “increases” but with zero shares and NaN changes, indicating erroneous/unclear short-interest reporting rather than a meaningful squeeze or piling on. Investors should treat those items cautiously.
• Negative Sentiment: EPS miss and margin concerns — Ardelyx reported EPS of ($0.01) vs. consensus $0.02, and commentary showed heavy operational spend that clouds near-term profitability; that miss is the primary near-term driver of selling pressure. Zacks Q4 EPS coverage
• Negative Sentiment: Mixed investor reaction to outlook — post-earnings commentary and coverage highlighted concerns about the IBSRELA outlook and high operating expenses, which prompted the stock decline despite strong sales numbers. Seeking Alpha: Strong IBSRELA Growth, But Heavy Operational Spend Clouds Profitability

Ardelyx Company Profile

Ardelyx, Inc (NASDAQ: ARDX) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.